- Company Offers Access to Archived Web Cast and Phone Replay of the Forum
FREMONT, Calif., May 1 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, recently held a roundtable teleconference focusing on its peripheral artery disease (PAD) diagnostic program and the need for improved detection of this life- and limb-threatening condition. The teleconference, which took place yesterday, featured keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at Stanford University, whose research forms the basis of Vermillion's PAD blood test.
The roundtable discussion was the first of a series of calls to provide investors an opportunity to hear more about Vermillion's diagnostic programs and understand the various markets that the company seeks to address. Yesterday's forum served as a means to educate this audience about the current state of PAD and why there is a clinical need for a blood test that can determine a person's risk of developing the disease. PAD, a serious condition affecting some eight to 12 million Americans, can double a person's risk of heart attack and stroke, and increase the risk of amputation and death. There are treatments that can save the lives and limbs of these patients once the disease is recognized.
"The signs and symptoms of PAD often go unnoticed, and as a result many
patients are not being properly diagnosed. We are in serious need of new,
innovative tools to aid in the diagnosis and management of this life-
threatening condition," said Dr. Cooke. "Together with Vermillion, we are
working to develop a simple blood test that will stratify an individual's
risk of developing PAD. This will serve as an important
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved